CX Institutional’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21K Hold
444
﹤0.01% 1168
2026
Q1
$16K Sell
444
-104
-19% -$4.93K ﹤0.01% 1183
2025
Q4
$28K Buy
548
+68
+14% +$3.48K ﹤0.01% 1065
2025
Q3
$27K Hold
480
﹤0.01% 1050
2025
Q2
$33K Sell
480
-42
-8% -$2.86K ﹤0.01% 911
2025
Q1
$36K Buy
+522
New +$43.1K ﹤0.01% 884
2022
Q3
Sell
-1,000
Closed -$56K 919
2022
Q2
$56K Buy
+1,000
New +$55.5K ﹤0.01% 654
2021
Q4
Sell
-1,000
Closed -$48K 731
2021
Q3
$48K Hold
1,000
﹤0.01% 589
2021
Q2
$42K Hold
1,000
﹤0.01% 593
2021
Q1
$34K Hold
1,000
﹤0.01% 568
2020
Q4
$35K Hold
1,000
﹤0.01% 503
2020
Q3
$35K Hold
1,000
﹤0.01% 447
2020
Q2
$33K Sell
1,000
-2,000
-67% -$63.8K ﹤0.01% 376
2020
Q1
$90K Buy
+3,000
New +$89.3K 0.01% 276

Other funds holding NVO

CX Institutional's NVO Position: Q2 2026 in Review

CX Institutional held its Novo Nordisk (NVO) position steady in Q2 2026 at 444 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

CX Institutional first reported a position in NVO in Q1 2020 and has held it in 14 quarters since. The position peaked at $90K in Q1 2020. 272 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • CX Institutional held 444 shares of Novo Nordisk worth $21K as of Q2 2026.
  • CX Institutional left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1168 holding.
  • CX Institutional first reported a position in Novo Nordisk in Q1 2020 and has held it in 14 quarters since.
  • CX Institutional's Novo Nordisk position peaked at $90K in Q1 2020.
  • 272 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.